Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients

Inclusion criteria

• Male or female, aged ≥18 years and ≤75 years at the time of signing informed consent；
• BMI ≥28 kg/m2；
• A self-reported change in body weight no more than 5% within 90 days before screening.

Exclusion criteria

• History of type 1 and type 2 diabetes;
• Previous or planned (during the trial period) obesity treatment with surgery or a weight-loss device;
• History or presence of chronic or acute pancreatitis;
• Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma;
• A history or presence of suspected depression or other mental disorders;
• Patient Health Questionnaire-9 score of ≥15 at screening
• Uncontrolled hypertension, any of the following: myocardial infarction, stroke, hospitalisation for unstable angina, or transient ischaemic attack within the past 6 months prior to screening;
• History of malignant neoplasms within the past 5 years prior to screening;